Wesco International Free cash flow increased by 620.0% to $198.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2505.3%, from $7.60M to $198.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $64.90M | -$187.20M | -$148.90M | -$133.90M | -$269.30M | $287.20M | $342.40M | $40.60M | $725.90M | $272.90M | $252.30M | $7.60M | $86.00M | -$95.90M | $27.50M | $198.00M |
| QoQ Change | — | -388.5% | +20.5% | +10.1% | -101.1% | +206.6% | +19.2% | -88.1% | >999% | -62.4% | -7.5% | -97.0% | >999% | -211.5% | +128.7% | +620.0% |
| YoY Change | — | — | — | -306.3% | -43.9% | +292.9% | +355.7% | — | +369.6% | -20.3% | +521.4% | -99.0% | — | -135.1% | -89.1% | >999% |